Mechanisms for the modulation of dopamine D 1 receptor signaling in striatal neurons

Frontiers in Neuroanatomy

Volumn , Issue JULY, 2011, Pages

  Nishi, Akinori ^a,b   Kuroiwa, Mahomi ^a,b   Shuto, Takahide ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

D 1; DARPP 32; Dopamine; Phosphodiesterase; Receptor; Signaling; Striatum

Indexed keywords

ADENYLATE CYCLASE; CASEIN KINASE I; CASEIN KINASE II; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 5; DOPAMINE 1 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INOSITOL 1,4,5 TRISPHOSPHATE; NEUROTRANSMITTER; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 1B; PHOSPHODIESTERASE IV; PHOSPHOLIPASE C; PHOSPHOPROTEIN DARPP 32; PROTEIN G OLF; PROTEIN TYROSINE KINASE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

COGNITION; CORPUS STRIATUM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; MOTOR PERFORMANCE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 84857743613     PISSN: 16625129     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnana.2011.00043     Document Type: Review

References (121)

1. Ahn, J. H., McAvoy, T., Rakhilin, S. V., Nishi, A., Greengard, P., and Nairn, A. C. (2007a). Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc. Natl. Acad. Sci. U.S.A. 104, 2979-2984.
2. Ahn, J. H., Sung, J. Y., McAvoy, T., Nishi, A., Janssens, V., Goris, J., Greengard, P., and Nairn, A. C. (2007b). The B/PR72 subunit mediates Ca2+- dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proc. Natl. Acad. Sci. U.S.A. 104, 9876-9881.
3. Bateup, H. S., Santini, E., Shen, W., Birnbaum, S., Valjent, E., Surmeier, D. J., Fisone, G., Nestler, E. J., and Greengard, P. (2010). Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc. Natl. Acad. Sci. U.S.A. 107, 14845-14850.
4. Bateup, H. S., Svenningsson, P., Kuroiwa, M., Gong, S., Nishi, A., Heintz, N., and Greengard, P. (2008). Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 11, 932-939.
5. Beaulieu, J. M., and Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182-217.
6. Beavo, J. A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75, 725-748.
7. Bender, A. T., and Beavo, J. A. (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488-520.
8. Bertran-Gonzalez, J., Bosch, C., Maroteaux, M., Matamales, M., Herve, D., Valjent, E., and Girault, J. A. (2008). Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci. 28, 5671-5685.
9. Bertran-Gonzalez, J., Herve, D., Girault, J. A., and Valjent, E. (2010). What is the degree of segregation between striatonigral and striatopallidal projections? Front. Neuroanat. 4:136. doi: 10.3389/fnana.2010.00136
10. Bibb, J. A., Chen, J., Taylor, J. R., Svenningsson, P., Nishi, A., Snyder, G. L., Yan, Z., Sagawa, Z. K., Ouimet, C. C., Nairn, A. C., Nestler, E. J., and Greengard, P. (2001). Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 410, 376-380.
11. Bibb, J. A., Snyder, G. L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A. A., Tsai, L. H., Kwon, Y. T., Girault, J. A., Czernik, A. J., Huganir, R. L., Hemmings, H. C. Jr., Nairn, A. C., and Greengard, P. (1999). Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402, 669-671.
12. Borgkvist, A., and Fisone, G. (2007). Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons. Neurosci. Biobehav. Rev. 31, 79-88.
13. Bromberg-Martin, E. S., Matsumoto, M., and Hikosaka, O. (2010). Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 68, 815-834.
14. Cherry, J. A., and Davis, R. L. (1999). Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 407, 287-301.
15. Chubb, J. E., Bradshaw, N. J., Soares, D. C., Porteous, D. J., and Millar, J. K. (2008). The DISC locus in psychiatric illness. Mol. Psychiatry 13, 36-64.
16. Clapcote, S. J., Lipina, T. V., Millar, J. K., Mackie, S., Christie, S., Ogawa, F., Lerch, J. P., Trimble, K., Uchiyama, M., Sakuraba, Y., Kaneda, H., Shiroishi, T., Houslay, M. D., Henkelman, R. M., Sled, J. G., Gondo, Y., Porteous, D. J., and Roder, J. C. (2007). Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54, 387-402.
17. Conti, M., and Beavo, J. (2007). Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511.
18. Cools, R. (2011). Dopaminergic control of the striatum for high-level cognition. Curr. Opin. Neurobiol. 21, 402-407.
19. Desdouits, F., Siciliano, J. C., Greengard, P., and Girault, J.-A. (1995a). Dopamineand cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. Proc. Natl. Acad. Sci. U.S.A. 92, 2682-2685.
20. Desdouits, F., Cohen, D., Nairn, A. C., Greengard, P., and Girault, J.-A. (1995b). Phosphorylation of DARPP-32, a dopamineand cAMPregulated phosphoprotein, by casein kinase I in vitro and in vivo. J. Biol. Chem. 270, 8772-8778.
21. Deveney, A. M., and Waddington, J. L. (1995). Pharmacological characterization of behavioural responses to SK&F 83959 in relation to D1-like dopamine receptors not linked to adenylyl cyclase. Br. J. Pharmacol. 116, 2120-2126.
22. Dunah, A. W., and Standaert, D. G. (2001). Dopamine D1 receptordependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21, 5546-5558.
23. Ehrman, L. A., Williams, M. T., Schaefer, T. L., Gudelsky, G. A., Reed, T. M., Fienberg, A. A., Greengard, P., and Vorhees, C. V. (2006). Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32- dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav. 5, 540-551.
24. Fasano, S., D'Antoni, A., Orban, P. C., Valjent, E., Putignano, E., Vara, H., Pizzorusso, T., Giustetto, M., Yoon, B., Soloway, P., Maldonado, R., Caboche, J., and Brambilla, R. (2009). Ras-guanine nucleotidereleasing factor 1 (Ras-GRF1) controls activation of extracellular signal-regulated kinase (ERK) signaling in the striatum and long-term behavioral responses to cocaine. Biol. Psychiatry 66, 758-768.
25. Felder, C. C., Jose, P. A., and Axelrod, J. (1989). The dopamine1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase. J. Pharmacol. Exp. Ther. 248, 171-175.
26. Fernandez, E., Schiappa, R., Girault, J. A., and Le Novere, N. (2006). DARPP-32 is a robust integrator of dopamine and glutamate signals. PLoS Comput. Biol. 2, e176. doi:10.1371/journal.pcbi.0020176
27. Fienberg, A. A., and Greengard, P. (2000). The DARPP-32 knockout mouse. Brain Res. Brain Res. Rev. 31, 313-319.
28. Fienberg, A. A., Hiroi, N., Mermelstein, P., Song, W.-J., Snyder, G. L., Nishi, A., Cheramy, A., O'Callaghan, J. P., Miller, D., Cole, D., Corbett, R., Haile, C., Cooper, D., Onn, S., Grace, A. A., Ouimet, C., White, F. J., Hyman, S. E., Surmeier, D. J., Girault, J. A., Nestler, E., and Greengard, P. (1998). DARPP-32, regulator of the efficacy of dopaminergic neurotransmission. Science 281, 838-842.
29. Fiorentini, C., Busi, C., Gorruso, E., Gotti, C., Spano, P., and Missale, C. (2008). Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol. 74, 59-69.
30. Fisone, G., Hakansson, K., Borgkvist, A., and Santini, E. (2007). Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms. Physiol. Behav. 92, 8-14.
31. Friedman, E., Jin, L. Q., Cai, G. P., Hollon, T. R., Drago, J., Sibley, D. R., and Wang, H. Y. (1997). D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. Mol. Pharmacol. 51, 6-11.
32. Fujishige, K., Kotera, J., Michibata, H., Yuasa, K., Takebayashi, S., Okumura, K., and Omori, K. (1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. 274, 18438-18445.
33. Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. M., Monsma, F. J. Jr., and Sibley, D. R. (1990). D1 and D2 dopamine receptorregulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
34. Gerfen, C. R., Miyachi, S., Paletzki, R., and Brown, P. (2002). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 22, 5042-5054.
35. Gerfen, C. R., and Surmeier, D. J. (2011). Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 34, 441-466.
36. Gines, S., Hillion, J., Torvinen, M., Le Crom, S., Casado, V., Canela, E. I., Rondin, S., Lew, J. Y., Watson, S., Zoli, M., Agnati, L. F., Verniera, P., Lluis, C., Ferre, S., Fuxe, K., and Franco, R. (2000). Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. U.S.A. 97, 8606-8611.
37. Girault, J. A., Valjent, E., Caboche, J., and Herve, D. (2007). ERK2: a logical AND gate critical for drug-induced plasticity? Curr. Opin. Pharmacol. 7, 77-85.
38. Girault, J.-A., Hemmings, H. C. Jr., Williams, K. R., Nairn, A. C., and Greengard, P. (1989). Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphorprotein, by casein kinase II. J. Biol. Chem. 264, 21748-21759.
39. Grauer, S. M., Pulito, V. L., Navarra, R. L., Kelly, M., Kelley, C., Graf, R., Langen, B., Logue, S., Brennan, J., Jiang, L., Charych, E., Egerland, U., Liu, F., Marquis, K. L., Malamas, M., Hage, T., Comery, T. A., and Brandon, N. J. (2009). PDE10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia. J. Pharmacol. Exp. Ther. 331, 574-590.
40. Greengard, P., Allen, P. B., and Nairn, A. C. (1999). Beyond the dopamine receptor: the DARPP- 32/protein phosphatase-1 cascade. Neuron 23, 435-447.
41. Hallett, P. J., Spoelgen, R., Hyman, B. T., Standaert, D. G., and Dunah, A. W. (2006). Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylationdependent subunit trafficking. J. Neurosci. 26, 4690-4700.
42. Halpain, S., Girault, J.-A., and Greengard, P. (1990). Activation of NMDA receptors induced dephosphorylation of DARPP-32 in rat striatal slices. Nature 343, 369-372.
43. Hara, M., Fukui, R., Hieda, E., Kuroiwa, M., Bateup, H. S., Kano, T., Greengard, P., and Nishi, A. (2010). Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons. J. Neurochem. 113, 1046-1059.
44. Hasbi, A., Fan, T., Alijaniaram, M., Nguyen, T., Perreault, M. L., O'Dowd, B. F., and George, S. R. (2009). Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc. Natl. Acad. Sci. U.S.A. 106, 21377-21382.
45. Hasbi, A., O'Dowd, B. F., and George, S. R. (2010). Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms. Curr. Opin. Pharmacol. 10, 93-99.
46. Heiman, M., Schaefer, A., Gong, S., Peterson, J. D., Day, M., Ramsey, K. E., Suarez-Farinas, M., Schwarz, C., Stephan, D. A., Surmeier, D. J., Greengard, P., and Heintz, N. (2008). A translational profiling approach for the molecular characterization of CNS cell types. Cell 135, 738-748.
47. 2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurinsignaling cascade. J. Neurosci. 20, 8987-8995.
48. Hersch, S. M., Ciliax, B. J., Gutekunst, C. A., Rees, H. D., Heilman, C. J., Yung, K. K., Bolam, J. P., Ince, E., Yi, H., and Levey, A. I. (1995). Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 15, 5222-5237.
49. Herve, D., Le Moine, C., Corvol, J. C., Belluscio, L., Ledent, C., Fienberg, A. A., Jaber, M., Studler, J. M., and Girault, J. A. (2001). Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J. Neurosci. 21, 4390-4399.
50. Houslay, M. D. (2010). Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem. Sci. 35, 91-100.
51. Houslay, M. D., and Adams, D. R. (2003). PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370, 1-18.
52. Hyman, S. E., and Malenka, R. C. (2001). Addiction and the brain: the neurobiology of compulsion and its persistence. Nat. Rev. Neurosci. 2, 695-703.
53. Jackson, D. M., and Westlind-Danielsson, A. (1994). Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol. Ther. 64, 291-370.
54. Janssens, V., Jordens, J., Stevens, I., Van Hoof, C., Martens, E., De Smedt, H., Engelborghs, Y., Waelkens, E., and Goris, J. (2003). Identification and functional analysis of two Ca2+-binding EF-hand motifs in the B/PR72 subunit of protein phosphatase 2A. J. Biol. Chem. 278, 10697-10706.
55. Jin, L. Q., Goswami, S., Cai, G., Zhen, X., and Friedman, E. (2003). SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J. Neurochem. 85, 378-386.
56. Jin, L. Q., Wang, H. Y., and Friedman, E. (2001). Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions. J. Neurochem. 78, 981-990.
57. Kebabian, J. W., and Calne, D. B. (1979). Multiple receptors for dopamine. Nature 277, 93-96.
58. Kitaoka, S., Furuyashiki, T., Nishi, A., Shuto, T., Koyasu, S., Matsuoka, T., Miyasaka, M., Greengard, P., and Narumiya, S. (2007). Prostaglandin E2 acts on EP1 receptor and amplifies both dopamine D1 and D2 receptor signaling in the striatum. J. Neurosci. 27, 12900-12907.
59. Kuroiwa, M., Bateup, H. S., Shuto, T., Higashi, H., Tanaka, M., and Nishi, A. (2008). Regulation of DARPP- 32 phosphorylation by three distinct dopamine D1-like receptor signaling pathways in the neostriatum. J. Neurochem. 107, 1014-1026.
60. Lee, F. J., Xue, S., Pei, L., Vukusic, B., Chery, N., Wang, Y., Wang, Y. T., Niznik, H. B., Yu, X. M., and Liu, F. (2002). Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111, 219-230.
61. Lee, S. P., So, C. H., Rashid, A. J., Varghese, G., Cheng, R., Lanca, A. J., O'Dowd, B. F., and George, S. R. (2004). Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 279, 35671-35678.
62. Lindskog, M., Svenningsson, P., Fredholm, B., Greengard, P., and Fisone, G. (1999). Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur. J. Neurosci. 11, 2182-2186.
63. Lindskog, M., Svenningsson, P., Pozzi, L., Kim, Y., Fienberg, A. A., Bibb, J. A., Fredholm, B. B., Nairn, A. C., Greengard, P., and Fisone, G. (2002). Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418, 774-778.
64. Mahan, L. C., Burch, R. M., Monsma, F. J. Jr., and Sibley, D. R. (1990). Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilization in Xenopus oocytes. Proc. Natl. Acad. Sci. U.S.A. 87, 2196-2200.
65. Marcellino, D., Ferre, S., Casado, V., Cortes, A., Le Foll, B., Mazzola, C., Drago, F., Saur, O., Stark, H., Soriano, A., Barnes, C., Goldberg, S. R., Lluis, C., Fuxe, K., and Franco, R. (2008). Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J. Biol. Chem. 283, 26016-26025.
66. McCahill, A. C., Huston, E., Li, X., and Houslay, M. D. (2008). PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. Handb. Exp. Pharmacol. 186, 125-166.
67. Menegoz, M., Lau, L. F., Herve, D., Huganir, R. L., and Girault, J. A. (1995). Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 7, 125-128.
68. Menniti, F. S., Faraci, W. S., and Schmidt, C. J. (2006). Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 5, 660-670.
69. Millar, J. K., Pickard, B. S., Mackie, S., James, R., Christie, S., Buchanan, S. R., Malloy, M. P., Chubb, J. E., Huston, E., Baillie, G. S., Thomson, P. A., Hill, E. V., Brandon, N. J., Rain, J. C., Camargo, L. M., Whiting, P. J., Houslay, M. D., Blackwood, D. H., Muir, W. J., and Porteous, D. J. (2005). DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310, 1187-1191.
70. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., and Caron, M. G. (1998). Dopamine receptors: from structure to function. Physiol. Rev. 78, 189-225.
71. Murdoch, H., Mackie, S., Collins, D. M., Hill, E. V., Bolger, G. B., Klussmann, E., Porteous, D. J., Millar, J. K., and Houslay, M. D. (2007). Isoform-selective susceptibility of DISC1/phosphodiesterase- 4 complexes to dissociation by elevated intracellular cAMP levels. J. Neurosci. 27, 9513-9524.
72. Nishi, A., Bibb, J. A., Matsuyama, S., Hamada, M., Higashi, H., Nairn, A. C., and Greengard, P. (2002). Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J. Neurochem. 81, 832-841.
73. Nishi, A., Bibb, J. A., Snyder, G. L., Higashi, H., Nairn, A. C., and Greengard, P. (2000). Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. U.S.A. 97, 12840-12845.
74. Nishi, A., Kuroiwa, M., Miller, D. B., O'Callaghan, J. P., Bateup, H. S., Shuto, T., Sotogaku, N., Fukuda, T., Heintz, N., Greengard, P., and Snyder, G. L. (2008). Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J. Neurosci. 28, 10460-10471.
75. Nishi, A., and Snyder, G. L. (2010). Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J. Pharmacol. Sci. 114, 6-16.
76. Nishi, A., Snyder, G. L., and Greengard, P. (1997). Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17, 8147-8155.
77. Nishi, A., Snyder, G. L., Nairn, A. C., and Greengard, P. (1999). Role of calcineurin and protein phosphatase- 2A in the regulation of DARPP- 32 dephosphorylation in neostriatal neurons. J. Neurochem. 72, 2015-2021.
78. Nishi, A., Watanabe, Y., Higashi, H., Tanaka, M., Nairn, A. C., and Greengard, P. (2005). Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc. Natl. Acad. Sci. U.S.A. 102, 1199-1204.
79. O'Sullivan, G. J., Roth, B. L., Kinsella, A., and Waddington, J. L. (2004). SK&F 83822 distinguishes adenylyl cyclase from phospholipase Ccoupled dopamine D1-like receptors: behavioural topography. Eur. J. Pharmacol. 486, 273-280.
80. Ouimet, C. C., and Greengard, P. (1990). Distribution of DARPP-32 in the basal ganglia: an electron microscopic study. J. Neurocytol. 19, 39-52.
81. Panchalingam, S., and Undie, A. S. (2001). SKF83959 exhibits biochemical agonism by stimulating [(35)S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40, 826-837.
82. Pascoli, V., Besnard, A., Herve, D., Pages, C., Heck, N., Girault, J. A., Caboche, J., and Vanhoutte, P. (2011). Cyclic adenosine monophosphateindependent tyrosine phosphorylation of NR2B mediates cocaine-induced extracellular signal-regulated kinase activation. Biol. Psychiatry 69, 218-227.
83. Perez-Torres, S., Miro, X., Palacios, J. M., Cortes, R., Puigdomenech, P., and Mengod, G. (2000). Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat. 20, 349-374.
84. Polli, J. W., and Kincaid, R. L. (1994). Expression of calmodulindependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J. Neurosci. 14, 1251-1261.
85. Rashid, A. J., O'Dowd, B. F., Verma, V., and George, S. R. (2007a). Neuronal Gq/11-coupled dopamine receptors: an uncharted role for dopamine. Trends Pharmacol. Sci. 28, 551-555.
86. Rashid, A. J., So, C. H., Kong, M. M., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B. F., and George, S. R. (2007b). D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. U.S.A. 104, 654-659.
87. Rebholz, H., Nishi, A., Liebscher, S., Nairn, A. C., Flajolet, M., and Greengard, P. (2009). CK2 negatively regulates Galphas signaling. Proc. Natl. Acad. Sci. U.S.A. 106, 14096-14101.
88. Reed, T. M., Repaske, D. R., Snyder, G. L., Greengard, P., and Vorhees, C. V. (2002). Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J. Neurosci. 22, 5188-5197.
89. Reid, M. S., Hsu, K. Jr., and Berger, S. P. (1997). Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: studies on the involvement of dopamine. Synapse 27, 95-105.
90. Sahu, A., Tyeryar, K. R., Vongtau, H. O., Sibley, D. R., and Undieh, A. S. (2009). D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Mol. Pharmacol. 75, 447-453.
91. Sano, H., Nagai, Y., Miyakawa, T., Shigemoto, R., and Yokoi, M. (2008). Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J. Neurochem. 105, 546-556.
92. Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J. A., Herve, D., Greengard, P., and Fisone, G. (2007). Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA- induced dyskinesia. J. Neurosci. 27, 6995-7005.
93. Schmidt, C. J., Chapin, D. S., Cianfrogna, J., Corman, M. L., Hajos, M., Harms, J. F., Hoffman, W. E., Lebel, L. A., McCarthy, S. A., Nelson, F. R., Proulx-LaFrance, C., Majchrzak, M. J., Ramirez, A. D., Schmidt, K., Seymour, P. A., Siuciak, J. A., Tingley, F. D. III, Williams, R. D., Verhoest, P. R., and Menniti, F. S. (2008). Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 325, 681-690.
94. Schmitz, Y., Benoit-Marand, M., Gonon, F., and Sulzer, D. (2003). Presynaptic regulation of dopaminergic neurotransmission. J. Neurochem. 87, 273-289.
95. Shuto, T., and Nishi, A. (2011). Treatment of the psychostimulantsensitized animal model of schizophrenia. CNS Neurosci. Ther. 17, 133-139.
96. Siuciak, J. A. (2008). The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22, 983-993.
97. Siuciak, J. A., Chapin, D. S., Harms, J. F., Lebel, L. A., McCarthy, S. A., Chambers, L., Shrikhande, A., Wong, S., Menniti, F. S., and Schmidt, C. J. (2006). Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51, 386-396.
98. Siuciak, J. A., McCarthy, S. A., Chapin, D. S., Reed, T. M., Vorhees, C. V., and Repaske, D. R. (2007). Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology 53, 113-124.
99. Stipanovich, A., Valjent, E., Matamales, M., Nishi, A., Ahn, J. H., Maroteaux, M., Bertran-Gonzalez, J., Brami-Cherrier, K., Enslen, H., Corbille, A. G., Filhol, O., Nairn, A. C., Greengard, P., Herve, D., and Girault, J. A. (2008). A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature 453, 879-884.
100. Strick, C. A., James, L. C., Fox, C. B., Seeger, T. F., Menniti, F. S., and Schmidt, C. J. (2010). Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropharmacology 58, 444-451.
101. Sulzer, D. (2011). How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69, 628-649.
102. Surmeier, D. J., Song, W. J., and Yan, Z. (1996). Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16, 6579-6591.
103. Svenningsson, P., Nairn, A. C., and Greengard, P. (2005). DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J. 7, E353-E360.
104. Svenningsson, P., Nishi, A., Fisone, G., Girault, J. A., Nairn, A. C., and Greengard, P. (2004). DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 44, 269-296.
105. Svenningsson, P., Tzavara, E. T., Liu, F., Fienberg, A. A., Nomikos, G. G., and Greengard, P. (2002). DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc. Natl. Acad. Sci. U.S.A. 99, 3188-3193.
106. Svenningsson, P., Tzavara, E. T., Qi, H., Carruthers, R., Witkin, J. M., Nomikos, G. G., and Greengard, P. (2007). Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J. Neurosci. 27, 4201-4209.
107. Tanda, K., Nishi, A., Matsuo, N., Nakanishi, K., Yamasaki, N., Sugimoto, T., Toyama, K., Takao, K., and Miyakawa, T. (2009). Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol. Brain 2, 19.
108. Threlfell, S., Sammut, S., Menniti, F. S., Schmidt, C. J., and West, A. R. (2009). Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J. Pharmacol. Exp. Ther. 328, 785-795.
109. Toda, S., Alguacil, L. F., and Kalivas, P. W. (2003). Repeated cocaine administration changes the function and subcellular distribution of adenosine A1 receptor in the rat nucleus accumbens. J. Neurochem. 87, 1478-1484.
110. Tomiyama, K., McNamara, F. N., Clifford, J. J., Kinsella, A., Drago, J., Tighe, O., Croke, D. T., Koshikawa, N., and Waddington, J. L. (2002). Phenotypic resolution of spontaneous and D1-like agonist-induced orofacial movement topographies in congenic dopamine D1A receptor knockout mice. Neuropharmacology 42, 644-652.
111. Undie, A. S., Berki, A. C., and Beardsley, K. (2000). Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways. Neuropharmacology 39, 75-87.
112. Undie, A. S., and Friedman, E. (1990). Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J. Pharmacol. Exp. Ther. 253, 987-992.
113. Undie, A. S., Weinstock, J., Sarau, H. M., and Friedman, E. (1994). Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J. Neurochem. 62, 2045-2048.
114. Valjent, E., Bertran-Gonzalez, J., Herve, D., Fisone, G., and Girault, J. A. (2009). Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. Trends Neurosci. 32, 538-547.
115. Valjent, E., Pascoli, V., Svenningsson, P., Paul, S., Enslen, H., Corvol, J. C., Stipanovich, A., Caboche, J., Lombroso, P. J., Nairn, A. C., Greengard, P., Herve, D., and Girault, J. A. (2005). Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U.S.A. 102, 491-496.
116. Walaas, S. I., and Greengard, P. (1984). DARPP-32, a dopamineand adenosine 3′:5′ -monophosphateregulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular disrtribution in rat brain. J. Neurosci. 4, 84-98.
117. Wang, H. Y., Undie, A. S., and Friedman, E. (1995). Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. Mol. Pharmacol. 48, 988-994.
118. Wittmann, M., Marino, M. J., Henze, D. A., Seabrook, G. R., and Conn, P. J. (2005). Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J. Pharmacol. Exp. Ther. 313, 594-603.
119. Xie, Z., Adamowicz, W. O., Eldred, W. D., Jakowski, A. B., Kleiman, R. J., Morton, D. G., Stephenson, D. T., Strick, C. A., Williams, R. D., and Menniti, F. S. (2006). Cellular and subcellular localization of PDE10A, a striatumenriched phosphodiesterase. Neuroscience 139, 597-607.
120. Yabuuchi, K., Kuroiwa, M., Shuto, T., Sotogaku, N., Snyder, G. L., Higashi, H., Tanaka, M., Greengard, P., and Nishi, A. (2006). Role of adenosine A(1) receptors in the modulation of dopamine D(1) and adenosine A(2a) receptor signaling in the neostriatum. Neuroscience 141, 19-25.
121. Zhang, Y., Loonam, T. M., Noailles, P. A., and Angulo, J. A. (2001). Comparison of cocaineand methamphetamineevoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions. Ann. N. Y. Acad. Sci. 937, 93-120.